

Amendment Tool

v1.6 06 December 2021

For office use

QC: Yes

Section 1: Project information

Short project title*:	The RECOVERY Trial			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281712			
Sponsor amendment reference number*:	Substantial Amendment 28			
Sponsor amendment date* (enter as DD/MM/YY):	23 May 2022			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	Following review of the current protocol, the change made with the urgent safety measure and known drug-drug interaction between dexamethasone and ritonavir (a component of Paxlovid) we wish to provide guidance to our investigators that any patient receiving Paxlovid should not receive dexamethasone, but an alternative corticosteroid (which does not interact with ritonavir) should be used instead.			
Project type (select):	Specific study			
	<div style="display: flex; justify-content: space-between;"> Research tissue bank Research database </div>			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes	No		
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	NHS/HSC REC			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes	No		
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	Yes	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes		No	
EudraCT number*:	2020-001113-21			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWoW) pilot)?:	Yes		No	
Did the study receive Pharmacy Assurance?:	Yes		No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes	No		
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes	No		
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes	No		
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes		No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	Yes	No		
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes	No		
Did the study involve children OR does the amendment introduce this?:	Yes		No	
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		No	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	Yes	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	Yes	Yes	Yes
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes

Section 2: Summary of change(s)

What do you want to update?:	Project information
	New site/PI only

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	CTIMP safety			
Specific change (select - only available when area of change is selected first)*:	Other - Please specify in the free text below			
Further information (free text - note that this field will adapt to the amount of text entered):	As ritonavir increases dexamethasone exposure and there is a risk of high-dose dexamethasone among patients on simple oxygen therapy (or no oxygen), we wish to avoid patients receiving Paxlovid from also receiving dexamethasone. We have therefore added advice to the protocol to guide investigators to use an alternative corticosteroid for such patients. There is good evidence that other corticosteroids (prednisolone, hydrocortisone) #are equally effective as dexamethasone. We will advise all investigators of this change, update our training materials and request that investigators explain the change sensitively to any participants currently receiving Paxlovid as part of the trial.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note) that this answer may affect the categorisation for the change):	All		Some	
Add another change				

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate	
<ul style="list-style-type: none"> I confirm that the Sponsor takes responsibility for the completed amendment tool I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf 	
Applicant identification:	Sponsor
	Legal representative of the sponsor Person or organisation authorised by the sponsor
Organisation:	University of Oxford
Name [first name and surname]*:	Heather House
Address:	CTRG, Boundary Brook House, Churchill Drive, Headington, Oxford OX3 7GB
Telephone number:	
Fax number:	
Purchase Order (PO) number for MHRA invoicing:	H62017838
Email address*:	ctr@admin.ox.ac.uk

Lock for submission
<p>Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.</p>
<div style="background-color: #90EE90; padding: 5px; display: inline-block;">Lock for submission</div>
<p>After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.</p>

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

Review bodies			
UK wide:	England and Wales:	Scotland:	Northern Ireland:

	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category:
Change 1:	Y	Y				Y				Y				Y				Y	A
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		
Overall Category:	A																		